Guizhou Yibai Pharmaceutical 過去の業績
過去 基準チェック /06
Guizhou Yibai Pharmaceutical's earnings have been declining at an average annual rate of -21.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 6.6% per year.
主要情報
-21.9%
収益成長率
-21.9%
EPS成長率
| Pharmaceuticals 業界の成長 | 10.9% |
| 収益成長率 | -6.6% |
| 株主資本利益率 | -8.8% |
| ネット・マージン | -9.8% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
収支内訳
Guizhou Yibai Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 2,398 | -236 | 1,481 | 117 |
| 30 Jun 24 | 2,509 | -131 | 1,517 | 116 |
| 31 Mar 24 | 2,709 | -9 | 1,589 | 112 |
| 31 Dec 23 | 2,821 | 103 | 1,587 | 112 |
| 30 Sep 23 | 2,773 | -453 | 1,509 | 122 |
| 30 Jun 23 | 2,769 | -425 | 1,516 | 123 |
| 31 Mar 23 | 2,731 | -433 | 1,497 | 129 |
| 31 Dec 22 | 2,735 | -426 | 1,533 | 127 |
| 30 Sep 22 | 2,840 | 143 | 1,628 | 125 |
| 30 Jun 22 | 3,106 | 200 | 1,801 | 125 |
| 31 Mar 22 | 3,210 | 223 | 1,871 | 128 |
| 31 Dec 21 | 3,347 | 244 | 1,986 | 136 |
| 30 Sep 21 | 3,586 | 335 | 2,075 | 153 |
| 30 Jun 21 | 3,627 | 279 | 2,153 | 149 |
| 31 Mar 21 | 3,551 | 240 | 2,110 | 165 |
| 31 Dec 20 | 3,413 | 229 | 2,043 | 146 |
| 30 Sep 20 | 3,286 | 176 | 2,043 | 89 |
| 30 Jun 20 | 3,225 | 161 | 2,073 | 106 |
| 31 Mar 20 | 3,224 | 143 | 2,092 | 108 |
| 31 Dec 19 | 3,361 | 142 | 2,164 | 119 |
| 30 Sep 19 | 3,480 | -765 | 2,291 | 132 |
| 30 Jun 19 | 3,599 | -789 | 2,265 | 122 |
| 31 Mar 19 | 3,744 | -768 | 2,334 | 85 |
| 31 Dec 18 | 3,883 | -725 | 2,363 | 77 |
| 30 Sep 18 | 3,845 | 268 | 2,292 | 99 |
| 30 Jun 18 | 3,748 | 370 | 2,154 | 100 |
| 31 Mar 18 | 3,841 | 388 | 2,228 | 83 |
| 31 Dec 17 | 3,808 | 388 | 2,197 | 71 |
| 30 Sep 17 | 3,877 | 411 | 2,177 | 30 |
| 30 Jun 17 | 3,913 | 396 | 2,265 | 0 |
| 31 Mar 17 | 3,881 | 403 | 2,252 | 0 |
| 31 Dec 16 | 3,687 | 385 | 2,205 | 0 |
| 30 Sep 16 | 3,519 | 317 | 2,265 | 0 |
| 30 Jun 16 | 3,439 | 302 | 2,278 | 0 |
| 31 Mar 16 | 3,364 | 214 | 2,359 | 0 |
| 31 Dec 15 | 3,303 | 189 | 2,333 | 0 |
| 30 Sep 15 | 3,532 | 332 | 2,379 | 0 |
| 30 Jun 15 | 3,496 | 372 | 2,320 | 0 |
| 31 Mar 15 | 3,223 | 482 | 2,008 | 0 |
| 31 Dec 14 | 3,157 | 478 | 1,980 | 0 |
| 30 Sep 14 | 3,120 | 483 | 1,941 | 0 |
| 30 Jun 14 | 3,001 | 463 | 1,844 | 0 |
| 31 Mar 14 | 2,886 | 441 | 1,781 | 0 |
| 31 Dec 13 | 2,785 | 429 | 1,709 | 0 |
質の高い収益: 600594 is currently unprofitable.
利益率の向上: 600594 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 600594 is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
成長の加速: Unable to compare 600594's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 600594 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
株主資本利益率
高いROE: 600594 has a negative Return on Equity (-8.8%), as it is currently unprofitable.